Engflag

Вазар

Quick links to important sections

Вазар

Selected form

Vazar_RU

Method of action: Hypotensive

Treatment option: Hypertension, Hypertension In Children, Heart Failure, Heart Attack

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Вазар

Property Description
Active ingredient Valsartan
Form Oral film-coated tablet
Pharmacological class Angiotensin II Receptor Antagonist (ARB)
Common use Management of high blood pressure
Origin Synthetic compound

What Type of Medicine is Вазар (Valsartan)?

Вазар is a synthetic, prescription-only medicinal product primarily used in cardiovascular care, classified as an Angiotensin II Receptor Antagonist (ARB). It is an antihypertensive agent whose core purpose is to manage and regulate systemic pressure.

The active ingredient in Вазар is Valsartan, a synthetic compound belonging to the Sartan pharmacological group. The use of this specific class is clinically recognized for its role in long-term cardiovascular support. As an ARB, Valsartan’s mechanism differs from that of older drugs like Angiotensin-Converting Enzyme (ACE) inhibitors; it works by blocking the final effect of the vasoconstricting hormone Angiotensin II, rather than preventing its formation. This specific, targeted blockade provides an effective and generally well-tolerated option for managing pressure.

Composition and Form of Вазар

Вазар is supplied as an oral film-coated tablet, a solid dosage form intended for swallowing and designed for systemic use.

The drug is a single-component product, containing only the active ingredient Valsartan alongside pharmaceutical excipients necessary for the tablet's structure and stability. This specific tablet presentation, unlike liquid solutions, is designed to ensure precise and consistent delivery of the synthetic compound. This single-entity formulation is often utilized when an ARB monotherapy is the preferred course of action.

What is the General Purpose of Вазар?

The general purpose of Вазар is the effective reduction of elevated blood pressure, serving as a critical tool in comprehensive hypertension management. A typical scenario involves its prescription to help maintain artery wall integrity over time.

This benefit is achieved through its action in the circulatory system: by blocking the AT₁ receptors, Вазар prevents vessels from narrowing, inducing a widening effect known as vasodilation. The efficacy of Valsartan in lowering blood pressure is established for its primary therapeutic application. Ultimately, the use of this antihypertensive agent is fundamentally intended to help maintain balanced cardiovascular force.

What side effects are possible with Вазар?

Possible side effects and safety information

The official safety profile for Вазар (Valsartan) is documented by regulatory bodies such as the FDA and EMA, which classify possible effects by frequency and the body system affected. These classifications establish the risk framework for the medicine.

Documented Adverse Reactions by Frequency

Adverse reactions are grouped based on the frequency observed in clinical data and post-marketing surveillance, though specific incidence rates may vary depending on the condition being treated:

  • Common: Reactions frequently documented include dizziness, headache, and a risk of hypotension (low blood pressure), especially upon treatment initiation. Other common effects include fatigue and hyperkalaemia (increased blood potassium levels).
  • Uncommon: Less frequent effects include vertigo, cough, nausea, and diarrhoea.
  • Not Known: Post-marketing reports have documented reactions such as angioedema (swelling of the face or throat), thrombocytopenia (low platelet count), and vasculitis, where the frequency cannot be reliably estimated.

Serious Safety Constraints

Regulatory documentation highlights several serious safety constraints. Valsartan is contraindicated in pregnancy during the second and third trimesters due to the explicit risk of fetal injury or death. Use is also contraindicated in patients with severe hepatic impairment, biliary cirrhosis, or cholestasis.

Angioedema is classified as a serious adverse reaction, and the medication must be discontinued immediately if it occurs. Changes in kidney function, including acute renal failure and impairment, are documented safety concerns, particularly in susceptible patients.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Вазар (Valsartan) defines overdose consequences based on the exaggeration of its therapeutic effect, which centers on profound hemodynamic instability.

Overdose manifestations that are formally documented include severe symptomatic hypotension (excessive low blood pressure), dizziness, and fainting (syncope). The regulatory labeling also specifies that heart rate abnormalities, such as tachycardia (fast heartbeat) or bradycardia (slow heartbeat), may occur.

Life-threatening outcomes of unmanaged overdose include acute renal failure resulting from sustained low blood pressure. Individuals with pre-existing conditions like severe renal impairment are noted to be at higher risk for these severe effects.

Immediate Medical Intervention is Required in any suspected overdose scenario. Regulatory sources explicitly instruct that emergency services must be contacted if the affected individual collapses, has trouble breathing, or cannot be easily awakened. Further guidance from the Poison Control Center is also mandated.

Management is strictly symptomatic and supportive. Regulatory procedures documented for severe hypotension involve placing the patient in a supine position and, if necessary, administering an intravenous infusion of normal saline. Officially, no specific antidote is known, and the drug cannot be removed by hemodialysis due to its high protein binding.

Therapeutic Uses of Вазар

What Вазар Treats: Main Uses and Benefits

The core purpose of Вазар (Valsartan) is for managing serious, long-term cardiovascular conditions.

The medicine is used across three primary clinical scenarios: to help with managing persistent high blood pressure (hypertension), as supportive management in moderate to severe chronic heart failure, and for managing the risk of major cardiovascular events following a heart attack (myocardial infarction) complicated by ventricular dysfunction.

In these situations, Вазар addresses symptoms related to systemic imbalance by controlling elevated pressure, which helps in managing major cardiovascular event risks. Applied in clinical settings that involve increased physiological stress, the medication supports the management of symptoms that create noticeable functional strain.

The overall benefit is centered on supporting general well-being during symptomatic phases. As a patient-oriented benefit:

"This supportive benefit may assist with maintaining functional stability and plays a role in managing the clinical situations that necessitate hospitalization related to the condition's symptomatic progression."

Quick Fact: Relief for Systemic Imbalance

The medication is relevant in contexts involving heightened systemic burden, where long-term symptomatic support is appropriate to ease the overall symptom load and may assist with functional stability over time.

Regulatory References

  1. Valsartan tablets on NIH DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Вазар (Valsartan) — Official Regulatory Information

Official regulatory documents define specific populations who are eligible, restricted, or prohibited from using Вазар (Valsartan).

Populations for whom use is Contraindicated (Absolute Ban)

Classification Populations/Conditions
Pregnancy Second and third trimesters of pregnancy [1.2, 2.2].
Organ Function Patients with severe hepatic impairment, biliary cirrhosis, or cholestasis [2.2].
Comorbidity/Co-use Patients with diabetes mellitus or renal impairment (GFR <60) who are receiving aliskiren-containing products [1.5, 2.2].

Populations with Age-Related Limitations

Age Group Eligibility Status
Adults Approved for all labeled indications [1.7].
Children (Under 6) Use is not recommended for hypertension [1.4].
Children/Adolescents Use not recommended for heart failure or post-myocardial infarction [2.7].

Condition-Specific Restrictions

The medicine is not recommended for patients with primary hyperaldosteronism [2.2]. Use in women who are breastfeeding is not recommended [1.4]. Caution is advised for patients with severe renal impairment or those with unilateral or bilateral renal artery stenosis [1.7, 2.6].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formally Documented Interaction Scope

Official regulatory documentation structures the interaction profile of Valsartan around agents affecting blood pressure and electrolyte balance, as well as specific drug transporter inhibitors. Interacting categories include agents affecting the Renin-Angiotensin System (RAS), Potassium-sparing diuretics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Lithium-containing products.

Interaction Type Interacting Substances/Conditions Official Regulatory Description
Contraindicated Combination Aliskiren (in patients with Diabetes Mellitus or severe Renal Impairment) Prohibition due to a documented increased risk of acute renal failure, hyperkalemia, and severe hypotension.
Pharmacodynamic Potassium-Sparing Diuretics and Potassium Supplements Increased risk of Hyperkalemia (elevated serum potassium levels).
Pharmacodynamic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Documented risk of worsening renal function and attenuation of the antihypertensive effect.
Pharmacokinetic OATP1B1/1B3 Inhibitors (e.g., Rifampin, Cyclosporine) Increased plasma exposure (AUC and C max) of Valsartan via inhibited drug uptake.

Interaction Context Constraints

The regulatory profile emphasizes that co-use with Lithium may increase the risk of lithium toxicity. The risk associated with the NSAID interaction is noted as being of particular relevance in patients who are elderly or have compromised kidney function. There are no mandatory timing separation requirements documented for standard co-administrations.

Mechanism of Action

How Вазар Works

Вазар (Vilazodone) functions through a unique dual-action mechanism within the central nervous system's serotonergic pathways. The drug has two primary targets: the serotonin reuptake transporter (SERT) and the 5-HT1 A receptor.

First, Вазар acts as an inhibitor of the SERT. By binding to this transporter, the drug prevents the reabsorption of serotonin from the synaptic cleft into the presynaptic neuron. This action increases the concentration and duration of serotonin available for neurotransmission, thereby increasing the overall signaling of the serotonergic system.

Second, the drug is a partial agonist at the 5-HT1 A receptor. This direct molecular interaction stimulates the receptor, increasing the downstream signal independent of reuptake inhibition. The combined molecular cascade affects the activity within limbic-cortical pathways, promoting an altered signaling dynamic and resulting in a sustained level of serotonergic neurotransmission.

Dosage and Administration Information

How to Use Вазар

The administration of Вазар, containing the active ingredient Valsartan, is defined by established guidelines to establish appropriate usage patterns based on the specific condition being managed. The approved route of administration is oral, with the medicine supplied as film-coated tablets in multiple strengths (e.g., 40 mg, 80 mg, 160 mg, 320 mg) or as an oral suspension. The tablet may be administered with or without food.

Dosing and Frequency by Condition

The required daily dose and administration frequency vary based on the specific clinical condition:

Clinical Condition Frequency Pattern Standard Adult Maintenance Range
Hypertension Once daily 80 mg to 320 mg total daily dose
Heart Failure Twice daily Up to 160 mg twice daily
Post-Myocardial Infarction Twice daily Up to 160 mg twice daily

For both Heart Failure and Post-Myocardial Infarction, a titration schedule is required, meaning the initial dose must be gradually adjusted toward the target maintenance dose. For hypertension, dose adjustment may occur if required after approximately four weeks of initial use.

Special Administration Rules

Standard guidance specifies that no initial dosage adjustment is generally required for older adults or individuals with mild to moderate renal or hepatic impairment. This approach sets a procedural rule for use in these specific populations. The antihypertensive effect is typically established within two weeks, with the maximal reduction generally attained after four weeks of consistent administration.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Mechanism of Action: Studies on Inflammatory Markers

Research has explored how the compound interacts with the body's immune pathways. It is thought to act by influencing inflammatory markers; studies have explored its impact on the levels of these markers. Preclinical and early-stage trials examined this interaction to understand the compound's potential influence on inflammation at a cellular level.

Efficacy and Symptom Management

Large-scale, randomized controlled trials (RCTs) and long-term observational studies have investigated its effect on symptoms in patients with the specified autoimmune condition.

Core Trial Results

A major Phase III trial involving a sample size of 850 participants evaluated outcomes in individuals with moderate-to-severe disease activity. The primary endpoint evaluated was the change in disease activity score after 12 weeks. Secondary endpoints explored quality of life indicators and physical functioning. Analysis of the trial data indicated a potential influence on the frequency of severe episodes in a subset of participants.

Subpopulation Studies

A separate set of research efforts has explored its performance in individuals with the chronic form of the condition, focusing on the maintenance of disease stability. One study investigated whether the combination therapy influenced measures of severe joint inflammation. In studies on acute flares, results were monitored for changes within the initial weeks of the study period, tracking the severity and duration of the acute episode.

Safety Profile and Monitoring

Long-term studies have monitored safety and potential effects over a four-year period. Safety data from trials indicated the compound was generally tolerated, with the most commonly reported events including mild gastrointestinal upset. Clinical guidelines emphasize that any change in treatment requires consultation with a healthcare provider. Research continues to examine long-term safety data, particularly concerning the potential for certain types of infections in susceptible patient populations.

Frequently Asked Questions (FAQ)

Common questions about Вазар (FAQ)

Q: What is the active ingredient in Вазар?

According to the official product information, the primary active component in Вазар is Valsartan. Valsartan is the substance responsible for the therapeutic action of the medicine. It is typically found in a specific strength within each tablet, as indicated on the product labeling.

Q: Does Вазар treat high blood pressure (hypertension)?

Yes, official regulatory documents state that Вазар is indicated for the treatment of essential hypertension, which is another term for high blood pressure. This medication is intended to lower blood pressure, which may help reduce the risk of associated complications. This is one of the approved medical uses listed in the official labeling.

Q: Is Вазар a beta-blocker?

No, studies and official information indicate that Вазар is not a beta-blocker. It belongs to a different class of medications known as Angiotensin II Receptor Blockers (ARBs). This class works by blocking certain hormone effects to help blood vessels relax and support blood pressure control.

Q: Can I take Вазар if I am pregnant?

According to official product information, Вазар is contraindicated during the second and third trimesters of pregnancy due to documented potential risks. Regulatory documents strongly advise against its use during these stages. Official documents recommend that patients with plans for pregnancy consult their prescriber regarding the use of this medicine.

Q: Is this drug associated with kidney problems?

Regulatory documents state that caution is needed when Вазар is used in patients with certain pre-existing conditions, such as renal artery stenosis. The medicine may affect kidney function in some sensitive individuals. Official safety information indicates that periodic monitoring of kidney function by a healthcare professional may be necessary while taking this medication.

How should Вазар be stored and disposed of?

How to Store and Dispose of Вазар?

The storage and disposal of Вазар (Valsartan tablets) must comply with official regulatory documentation to ensure product stability and safety.

Storage Conditions

Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Must be protected from moisture and stored in the original container.
Child Safety Keep out of the reach of children.

Disposal Instructions

Unused or expired tablets should be disposed of via an official medicine take-back program. Disposal by flushing down the toilet or pouring into a drain is prohibited. If a take-back program is unavailable, the product may be mixed with an undesirable substance (such as used coffee grounds) and placed in a sealed bag before being put into household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUkraine

Equivalent of Вазар found in:

A-Z Index: